Biogen Q4 2022 rev $2.54B; GAAP EPS $3.79; guides FY2023 Non-GAAP EPS $15-$16

BIOGEN INC.

2022-FY EPS reported $20.87 revenue$10,173,400,000

Q4 revenue $2,544M, GAAP EPS $3.79, Non-GAAP EPS $4.05.
FY2022 revenue $10,173M (-7% YoY); GAAP EPS $20.87; Non-GAAP EPS $17.67 (-8% YoY).
FY2023 guidance: mid-single digit revenue decline; Non-GAAP EPS $15.00-$16.00.
LEQEMBI (lecanemab) granted FDA accelerated approval; traditional filing submitted in US, EU, Japan, China.
Zuranolone NDA for MDD/PPD accepted with Priority Review; PDUFA date August 5, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported the fourth quarter and year ended December 31, 2022 results: revenue $2,544 million, net income GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05, EPS GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05.

Period: the fourth quarter and year ended December 31, 2022
Revenue: $2,544 million
Net income: GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05
EPS: GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05
Result: reported results

Exact text from the filing

growth drivers; Company reports full year 2022 results and provides full year 2023 guidance Full year 2022 revenue and Non-GAAP EPS exceed guidance • Fourth quarter revenue $2,544 million; GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05 • Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67 Positioned to lead in Alzheimer’s

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported full year 2023 results: EPS $15.00 to $16.00. Guidance initiated.

Period: full year 2023
EPS: $15.00 to $16.00
Guidance: initiated
Result: guidance update

Exact text from the filing

Full Year 2023 Financial Guidance • Expect mid-single digit revenue decline versus 2022 and Non-GAAP EPS of $15.00 to $16.00

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported full year 2022 results: revenue $10,173 million, net income GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67, EPS GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67.

Period: full year 2022
Revenue: $10,173 million
Net income: GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67
EPS: GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67
Result: reported results

Exact text from the filing

Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67

View on SEC.gov

Browse all earnings releases →

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0000875045-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.